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Sequencing-based breast cancer 
diagnostics as an alternative to 
routine biomarkers
Mattias Rantalainen1,*, Daniel Klevebring1,*, Johan Lindberg1,*, Emma Ivansson1, 
Gustaf Rosin2, Lorand Kis2,3, Fuat Celebioglu4, Irma Fredriksson5,6, Kamila Czene1, 
Jan Frisell5,6, Johan Hartman2,3, Jonas Bergh2,3,* & Henrik Grönberg1,*
Sequencing-based breast cancer diagnostics have the potential to replace routine biomarkers and 
provide molecular characterization that enable personalized precision medicine. Here we investigate 
the concordance between sequencing-based and routine diagnostic biomarkers and to what extent 
tumor sequencing contributes clinically actionable information. We applied DNA- and RNA-sequencing 
to characterize tumors from 307 breast cancer patients with replication in up to 739 patients. We 
developed models to predict status of routine biomarkers (ER, HER2,Ki-67, histological grade) from 
sequencing data. Non-routine biomarkers, including mutations in BRCA1, BRCA2 and ERBB2(HER2), 
and additional clinically actionable somatic alterations were also investigated. Concordance 
with routine diagnostic biomarkers was high for ER status (AUC = 0.95;AUC(replication) = 0.97) 
and HER2 status (AUC = 0.97;AUC(replication) = 0.92). The transcriptomic grade model 
enabled classification of histological grade 1 and histological grade 3 tumors with high accuracy 
(AUC = 0.98;AUC(replication) = 0.94). Clinically actionable mutations in BRCA1, BRCA2 and 
ERBB2(HER2) were detected in 5.5% of patients, while 53% had genomic alterations matching 
ongoing or concluded breast cancer studies. Sequencing-based molecular profiling can be applied as 
an alternative to histopathology to determine ER and HER2 status, in addition to providing improved 
tumor grading and clinically actionable mutations and molecular subtypes. Our results suggest that 
sequencing-based breast cancer diagnostics in a near future can replace routine biomarkers.
Advances in primary management of breast cancer have resulted in marked survival improvements, mainly 
due to abide use of different adjuvant therapies together with early detection using mammography1–7. Routine 
diagnostics, including assays of routine biomarkers (e.g. ER, PR, Ki-67 and HER2) and morphological features 
(histological grade), are important for selection of adjuvant treatment. However, current routine techniques for 
measuring biomarkers and morphological features are lacking precision8–11, thus leading to both under- and 
overtreatment of women with early breast cancer.
Breast cancer is a heterogeneous disease and stratification of patients based on the multivariate molecular 
phenotype of their primary tumor provides means for prognostication and prediction of the probability to reduce 
risk of relapse as an effect of adjuvant treatments. The subtypes originally defined by Sørlie et al. in 2001 and later 
further refined in additional studies12–18 are commonly used for stratification of tumors: Basal-like, Luminal A, 
Luminal B, HER2 and Normal-like. However, molecular subtyping using gene expression signatures has not yet 
reached wide implementation in the clinic. In current clinical practice this molecular phenotype is based on 
four biomarkers that are routinely analyzed by immunohistochemistry (IHC): Estrogen receptor alpha (ER), 
progesterone receptor (PR), Human epidermal growth factor 2 (HER2), and Ki-67. In addition, histopathological 
characterization is routinely carried out to determine tumor grade (Nottingham Histologic Grade). Additional 
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histopathological information of importance in the planning of adjuvant treatment include tumor size.nodal 
status and lymphovascular invasion. The molecular subtypes have demonstrated prognostic value12,16–18 and are 
associated with therapeutic targets (e.g. ER and HER2) and predictive of reduced risk of relapse after treatment. 
The PAM50 panel18 classifies tumor samples into the intrinsic subtypes with a demonstrated prognostic perfor-
mance beyond conventional clinical factors17,19.
Cancer diagnostics based on molecular profiling, particularly DNA- and RNA-sequencing, could improve the 
precision of cancer diagnosis by providing comprehensive tumor characterization20,21, likely enabling the oppor-
tunity for better management and personalized treatment based on tumor characteristics.
In this study we evaluate to what extent DNA- and RNA-sequencing-based molecular profiling of primary 
breast cancer tumors can directly replace and augment current routine diagnostic biomarkers. A prerequi-
site for clinical implementation is cost-efficiency. Therefore we designed a 1.6 Mb pan-cancer panel to enable 
detection of point mutations, germ-line risk variants and pharmacogenomics SNPs. Additionally, low-pass 
whole-genome sequencing was performed for the identification of copy number variants. A full profile, also 
including RNA-sequencing, required in total only data corresponding to 1/5 lane on the Illumina Hiseq 2500, in 
high-output mode.
Using our full profile, we evaluate to what extent RNA-sequencing (RNAseq) data allow us to predict the status 
of routine breast cancer biomarkers (ER, PR, HER2 and Ki-67). We also outline how RNAseq data can be used to 
define transcriptomic grade, as an alternative to the histological grade. Furthermore, we detect clinically actiona-
ble somatic alterations, including those in ERBB2 (HER2) and BRCA1/BRCA2, which represent information with 
the potential to provide direct added value from sequencing-based diagnostics.
Materials and Methods
ClinSeq study. The study is based on samples from the Libro1 and KARMA tissue studies. Briefly, Libro1 
is a retrospectively enrolled group of patients who underwent surgery between 2001 and 2008 at the Karolinska 
University Hospital and KARMA is a prospectively enrolled group of patients from the South General Hospital 
in Stockholm during 2012. For both studies, germline DNA from blood and snap-frozen tumor tissue was avail-
able. In total the ClinSeq data set contained 307 individuals with RNAseq data (see Supplemental Fig. 1 for con-
sort diagram), low-pass whole-genome DNA sequencing (0.5× coverage) to determine genomic copy number 
variants (CNVs) across the genome, and panel DNA-sequencing (150× coverage) of 484 genes in an custom 
in-house designed pan-cancer gene panel for detection of point mutations, germ-line risk variants and pharma-
cogenomics SNPs. The panel was designed in June 2013 through extensive literature search. Additionally, the size 
of the panel was limited to enable 24 samples to be run simultaneously on one Illumina Hiseq 2500 lane in rapid 
mode. Information on ER, PR, HER2 and Ki-67 as well as histological grade was collected from medical records. 
The distribution of clinical biomarkers and phenotypes are provided in Supplemental Table 1. Written informed 
consent was obtained from all subjects. All experimental protocols were approved by the Regional Ethical Review 
Board in Stockholm (Reference number: 2013/1833–31/2). All experimental methods were conducted according 
to approved guidelines.
TCGA breast cancer study. Clinical data and unaligned RNAseq data from the TCGA dataset were down-
loaded from the TCGA data portal (N = 1073) with approval from the TCGA data access committee (dbGAP 
project ID 5621). 35 observations were excluded as potential outliers. ER status was available for 739 individuals, 
PR status for 738 individuals and HER2 status for 731 individuals, which were included in the replication of 
receptor status prediction. 507 individuals had histological grade (Elston-Ellis) available and were included in the 
replication of the transcriptomic grade model.
Tissue and library preparation, sequencing and preprocessing. Briefly, DNA libraries were con-
structed using ThruPlex-FD (Rubicon Genomics), one aliquot was used for low-pass WGS and one aliquot was 
used for capture using the EZ SeqCap kit (Roche Nimblegen) as previously described22. The capture kit contained 
484 genes known to be somatically mutated or associated with germline risk (Supplemental Table 2). Additionally, 
82 pharmacogenic SNPs were also included23. Sequencing was performed on Illumina HiSeq 2500. WGS libraries 
were sequenced to on average 0.5x coverage, captured libraries to around 150x average coverage and RNAseq 
libraries to a median of 33 million read-pairs per library (paired-end 2 × 101 bases). Preprocessing was per-
formed using AutoSeq (https://github.com/dakl/autoseq), which includes best practices pipelines for the respec-
tive data types.
Prediction modeling. Logistic regression models were fitted with ER, PR, HER2 status as response variable 
and the expression of each corresponding gene as predictor. Ki-67 was modeled by a linear penalized regression 
model, elastic-net24,25. Molecular subtypes were assigned using the Nearest Shrunken Centroid classifier26 using 
the PAM50 gene set18 with parameters estimated from the TCGA dataset, excluding Normal-like subtype as the 
clinical relevance of this subtype has been questioned27. Prediction modeling of histological grade aimed at clas-
sifying tumors into ‘high’ and ‘low’ transcriptomic grade (TG), corresponding to histological grade 1 and 3, was 
carried out using elastic-net models25, Individual elastic net models were fitted for each subcomponent of the 
histological grade: mitotic count, nuclear atypia and tubular formation. Each of these models was trained on 
tumors with a clinical score of 1 or 3 for each respective component. For prediction of transcriptomic grade, the 
predicted score (Yˆ) for each component were combined into an overall score defined by the sum over the predic-
tions from each subcomponent model, Yˆ_mitotic (mitotic count), Yˆ_nuclearity (nuclear atypia), Yˆ_tubularity 
(tublar formation). The transcriptomic grade model included 218 genes in total (Supplemental Table 2), 18 of 
these genes were common with the gene set of 97 genes previously proposed by Sotiriou et al.28 based on microar-
ray data. To estimate prediction performance in the case of penalized regression models, a nested cross-validation 
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procedure was implemented allowing for unbiased estimation of prediction performance while also optimizing 
model parameters empirically. Optimization of the amount of penalization (lambda) in each elastic net model 
was optimised in the inner cross-validation, using only the training data from the outer cross-validation. The 
parameter alpha, describing the relative weight between L1 and L2 penalisation was set to 0.5. The prediction 
performance was estimated using the test set in the outer cross-validation round, i.e. using data that were not 
involved in any part of the model optimization or parameter estimation. Prediction performance in all prediction 
models was evaluated using nested cross-validation. Optimal decision boundaries for binary classification prob-
lems were determined by the point with minimal distance to the top-left corner of the ROC curve. All statistical 
analyses were carried out in R29. See Supplemental Methods for further details.
Clinical routine biomarkers. Information on ER, PR, HER2 and Ki-67, as well as histological grade, was 
collected from medical records. ER and PR status were for most individuals assessed by immunohistochemistry 
(IHC), classifying tumors that showed staining in 10% or more cells as positive. For a subset of the older samples 
the radioimmunoassay was used to assess ER and PR status, classifying tumors that had > 0.05 fmol/ug DNA as 
positive. A tumor was classified as HER2 positive if fluorescence in situ hybridization (FISH) showed amplifica-
tion or, in the absence of FISH results, if the sample was graded 3+ by HER2 IHC. FISH was routinely carried out 
for tumors with > 2+ HER2 score determined by IHC. Ki-67 was assessed by IHC and medical records report 
Ki-67 either as “high”/“low” or as a percent value (% positively stained cells). For the tumors with reported per-
centage, 20% was considered as the threshold for high proliferation. Grade (Elston-Ellis) was recorded as 1, 2 or 3.
Histopathological re-examination. Re-examination of ER and HER2 was performed for individuals 
where the receptor status was discordant between sequencing-based assessment and routine pathology when 
biobanked material was accessible for re-examination. FFPE archived material was sectioned in 4 um, mounted 
and stained according to routine protocol at the Laboratory of Clinical Pathology and Cytology at Karolinska 
University Hospital30.
Actionable mutations. We identified somatic actionable alteration by matching somatic SNVs, indels 
(insertions and deletions), amplifications and deep deletions to the knowledge database generated by Dienstmann 
et al.31. When enumerating patients potentially eligible for targeted drugs, patients were only once counted as a 
match, and this to the candidate drug with the highest priority (Approved > Late phase studies > Early phase 
studies).
Please refer to the Supplemental Methods for further details.
Results
RNAseq-based prediction of routine biomarker status. To evaluate if the RNAseq profile can be uti-
lized to predict status of ER, PR, HER2 and Ki-67 we implemented prediction models (see methods) using the 
clinical status of each of these markers as response variable and RNAseq gene expression variables as predictors. 
Technical reproducibility was high (Supplemental Fig. 2). Results indicate that prediction of the conventional 
IHC-based markers5 can be achieved with high accuracy; Area under the Receiver Operating Characteristic 
curve (ROC-AUC) was estimated to 0.95 for ER (95% CI:0.93–0.96), 0.93 for PR (95%CI:0.92–0.94) and 0.97 
for HER2 (95%CI:0.97–0.98) (Fig. 1A–C). Status (high/low) of the proliferation marker Ki-67 was predicted 
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Figure 1. Classification performance of RNAseq-based prediction models for ER, PR, HER2 and Ki-67 as 
indicated by Receiver operating characteristic curves based on cross-validation for (A) ER, (B) PR, (C) HER2, 
(D) Ki-67. Boxplots of p(status = positive | RNAseq profile) (the probability of positive status of the marker (ER, 
PR or HER2) given the RNAseq expression profile data) from cross-validation for (E) ER, (F) PR, (G) HER2 
and (H) predicted (Yˆ) Ki-67 score (% positively stained cells) given RNAseq expression profile data. Dotted red 
lines indicate optimal decision boundaries as determined by ROC analyses, corresponding to the point on the 
ROC curve with minimal distance to the top-left corner.
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with ROC-AUC = 0.89 (95%CI:0.87–0.90) (Fig. 1D). Corresponding decision boundaries for ER, PR, HER2 
and Ki-67 are visualized in Fig. 1E,F. AUC estimates for ER, PR and HER2 status were replicated in the TCGA 
data set; clinical Ki-67 status was not available for analysis. AUC estimates in the TCGA study were similar to 
those in the ClinSeq study; 0.97 for ER (95%CI:0.95–0.98), 0.92 for PR (95%CI:0.90–0.95) and 0.92 for HER2 
(95%CI:0.89–0.96). There were no difference in AUC for ER and PR models between the ClinSeq and TCGA 
data sets (DeLong’s-test32, p-value(ER) = 0.07; p-value(PR) = 0.42). In the case of HER2 the AUC was found to be 
lower in TCGA study (DeLong’s-test32, p-value = 0.004), although the AUC is still to be considered high at 0.92. 
In this context AUC values > 0.9 is to be considered as high and indicative of good prediction performance. In our 
analyses, AUC values were estimated at ≥ 0.95 for several of the markers, indicating high prediction performance 
in general for these markers using RNAseq profiling.
ER and HER2 status have direct implications on the choice of adjuvant treatment. Therefore we have inves-
tigated a set of individuals with material available for re-examination and where sequencing-based ER or HER2 
status differed from the clinical status (Table 1). ER status was discordant between RNAseq-based calls and 
clinical ER status in 17 individuals (5.5%). 10 (out of 17) have undergone pathological re-examination where 
six of ten individuals (60%) were reclassified and concordant with RNAseq-based calls after re-examination 
(Table 1), indicating that these discordant cases might have been misclassified initially or had an intermediate 
phenotype. HER2 status was discordant between RNAseq-based calls and clinical HER2 status in eight individ-
uals (2.6%). Out of these, six individuals have undergone pathological re-examination and two out of six indi-
viduals (33%) were reclassified compared to initial pathological examination (Table 1). Using the CNV profile 
(low pass whole-genome sequencing), we investigated the copy number status of ERBB2 (HER2) for discord-
ant individuals classified as negative by the RNAseq model but positive by IHC/FISH. The CNV data indicate 
low-grade (ratio close to two) amplifications of the ERBB2 (HER2) locus on chromosome 17 for these individuals 
(Supplemental Figs 3–8).
Transcriptomic tumor grade. With the aim of improving stratification of patients by tumor grade, we 
applied a RNAseq-based multivariate prediction model to classify tumors into ‘high’ and ‘low’ transcriptomic 
grade (TG), corresponding to NHG 1 and 3. The model could classify grade 1 and grade 3 tumors with high 
accuracy (ROC-AUC = 0.98, 95% CI:0.97–0.98, Fig. 2A), indicating that the RNAseq based transcriptomic 
grade model can be utilized to correctly distinguish between histological grade 1 and grade 3 tumors. TG 
classification performance was replicated in the TCGA data set, confirming good classification performance 
(ROC-AUC = 0.94, 95% CI:0.91–0.97), but lower than in the ClinSeq study (DeLong’s-test32, p-value = 0.008). 
Next, we applied the model to reclassify grade 2 tumors in the ClinSeq study (N = 121) into high and low TG 
(Fig. 2B), since grade 2 status is not informative for clinical decision-making. 14(12%) of grade 2 tumors were 
reclassified as high TG, and 107(88%) as low TG. Figure 2B shows the reclassification patterns of all tumors in 
the study using the TG model. We observed no significant difference in subtype distribution (Fig. 2C) between 
high TG (TG High) and histological grade 3 (HG 3) (Fisher’s exact text, p-value = 0.85), and not between low TG 
(TG Low) and histological grade 1 (HG 1) (Fisher’s exact text, p-value = 0.86). This indicate that on a molecular 
subtype level the HG 1 and TG Low groups are similar, and the HG 3 and TG High groups are similar, suggesting 
Medical record Seq-based characterization Re-examination by IHC/SISH
Patient ID
Discordant 
marker ER HER2 ER HER2
HER2 
copy-
number* subtype ER%
HER2 
IHC ER HER2
HER2 
SISH
Concordant 
after re-
examination
RDK1 ER + − − − Basal 0 0 − Y
RDK2 ER − − + − LumA 100 0–1+ + Y
RDL1 ER + − − − Basal 0 0 − Y
RDL2 ER + − − − Basal 0 0 − Y
RDL3 ER + − − − Her2 0 2+ − Y
RDL4 ER + + − + Her2 0 3+ − Y
RDK3 ER + + − + Her2 20 3+ + N
RDL5-a ER + NA − + Her2 20 3+ + N
RDL5-b ER + NA − + Her2 80 2+ + N
RDL6 ER + − − − Her2 15 0 + N
RDL7 ER/HER2 + − − + low amp LumA 100 1+ + − NA N/N
RDL8-a HER2 + + + − low amp LumB 80 0 + − NA Y
RDL9 HER2 − − − + high amp Her2 0 3+ − + NA Y
RDL10 HER2 + + + − low amp LumB 100 1+ + + positive N
RDL8-b HER2 + + + − low amp LumB 90 1+ + + positive N
RDL11 HER2 + + + − low amp LumB 85 1+ –2+ + + positive N
RDL12 HER2 + + + − low amp LumB 100 3+ + + NA N
Table 1.  Histopathological re-examination results for individuals discordant for ER and HER2 status 
between routine pathology and sequencing-based analysis. *See Supplemental Figures 3–8. NA = missing/
unavailable data. Patients RDL5 and RDL8 had two separate tumor pieces re-examined by IHC/SISH (labeled as 
− a and − b) (Key: LumA = Luminal A, LumB = Luminal B, Her2 = Her2-enriched, Basal = Basal-like).
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the the TG model stratify patients in a way that is consistent with histological grade. We also found that histolog-
ical grade 2 tumors (HG 2) that were reclassified as low TG (Fig. 2C, HG2 & TG Low) had highly similar subtype 
distribution as histological grade 1 (HG 1), both dominated by Luminal A subtype, indicating that these reclassi-
fied tumors resembles the group of HG 1 tumors, suggesting that these reclassified HG 2 tumors on a molecular 
subtype level resembles the HG 1 group. Similarly, histological grade 2 tumors (HG 2) reclassified as high TG 
(Fig. 2C, HG2 & TG High) had a similar subtype distribution as histological grade 3 (HG 3), with a minority 
of Luminal A and domination of Luminal B and Her2 subtypes (we note that the HG2 & TG High group has 
no presence of Basal-like subtype tumors since no Basal-like subtype tumors were initially present in the HG 2 
group), again confirming that the TG model stratify patients in such a way that the distribution on the molecular 
subtype level is similar to histological grade. Next, we assessed the distribution of the clinical proliferation marker 
Ki-67 across histological grades and transcriptomic grades (Fig. 2D). We found that low TG and histological 
grade 1 displayed similar Ki-67 score distributions, albeit with a small but significant difference in mean scores 
(two-sided t-test, p-value = 0.004). High TG and histological grade 3 displayed similar Ki-67 scores distribution, 
with no significant difference in mean scores (two-sided t-test, p-value = 0.81). Altogether, these results suggest 
that the TG model has the potential to provide means for improved stratification of breast cancer patients by 
enabling a molecularly consistent reclassification of HG 2 patients into TG low and TG high.
Somatic mutations in ERBB2 (HER2). Next, we evaluated to what extent somatic mutations in ERBB2 
were present and detectable. Somatic mutations in ERBB2(HER2) have the potential to activate HER2 signaling 
without increased HER2 protein expression33, giving them no benefit from trastuzumab. Instead, small-molecule 
tyrosine kinase inhibitors such as lapatinib and neratinib have proven successful in model systems33 and have 
great potential to be of benefit for these patients, also indicated by preliminary results in humans34. We utilized 
panel DNA sequencing to ascertain mutations in ERBB2. In our study, five patients harbored somatic alterations 
in ERBB2(HER2), all at different positions (Fig. 3A). All but one (P1170A) of the mutations were included in 
COSMIC35, and two (L755S, V777L) were previously described as activating33. All of these patients were HER2 
negative by routine IHC, indicating a normal level of HER2 protein expression. One of these individuals (RDL6) 
was predicted to have a HER2-enriched molecular subtype. The group of patients harboring ERBB2 mutations 
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Figure 2. Transcriptomic tumor grade (TG) in comparison with histological grade and molecular subtype. 
(A) ROC curve from cross-validation predictions of histological grade 1 and grade 3 using the TG model. 
(B) Sankey graph of the reclassification of histological grade 1–3 into low TG and high TG. (C) Proportion 
of intrinsic subtypes stratified by histological grade (HG) (1–3) and TG (low, high), where ‘HG2 & TG High’ 
represents HG 2 tumors reclassified as TG High, and ‘HG2 & TG Low’ represents HG 2 tumors reclassified as 
TG Low. (D) Clinical Ki-67 scores (% positively stained cells) for histological grade (HG) (1–3) and TG (low, 
high).
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would normally not have been identified in the routine clinical setting, while DNA-sequencing in this case enable 
identification of these patients, which could have benefit from alternative treatments, as outlined above.
Somatic and germline mutations in BRCA1 and BRCA2. Furthermore, we applied panel DNA 
sequencing to investigate germline and somatic mutations in BRCA1 and BRCA2, due to their potential to impact 
both treatment and patient follow-up. In total, 12 patients harbored mutations in these genes (BRCA1; one 
somatic, four germline, BRCA2; four somatic, three germline) (Fig. 3B). All patients with germline mutations 
in BRCA1 (but none of the BRCA2-carriers) were predicted to carry a tumor with a basal-like subtype and the 
variants were all listed as known pathogenic in ClinVar36.
Other actionable somatic alterations. Through the application of panel DNA sequencing and low-pass 
whole genome DNA sequencing (CNV profiling) 162 patients (53%) in the ClinSeq study (Fig. 4A) were found to 
have potentially actionable genetic alterations that matched with 13 breast cancer studies on experimental agents 
Figure 3. (A) Overview of HER2 status, molecular subtype and specific ERBB2 mutation for those individuals 
with detected ERBB2 (HER2) somatic mutations. All tumors with somatic mutations in ERBB2 (HER2) were 
found to be HER2-negative according to both routine pathology and RNAseq-based classification, indicating 
normal HER2 expression levels. (B) Overview of transcriptomic grade, ER status, HER2 status, molecular 
subtype and BRCA1/2 mutations status of those individuals with detected germline or somatic mutations in 
either BRCA1 or BRCA2. Tumors in patients with germline alterations in BRCA1 are predominantly of the 
Basal-like subtype. (Key: TG = transcriptomic grade. Status: 0 = negative/low; 1 = positive/high).
Figure 4. Overview of somatic alterations that are potentially actionable in the ClinSeq study. (A) Each 
patient’s mutational profile was matched to the Dienstmann et al. knowledge base of actionable mutations 
including only breast cancer trials, excluding the ERBB2 amplification. Presence of a colored block in the 
intersection between an actionable mutation (rows in the heatmap) indicate a match between the somatic 
alterations in A patient (columns in the heatmap), Studies are classified as “Early” or “Late” from the 
Dienstmann et al. knowledge base31, also indicated by color. The top panel of display transcriptomic grade status 
(“TG”), molecular subtype (“PAM50”), ER status (“ESR1”) and HER2 status (“ERBB2”). (B) Summary of the 
number of patients in the present study that were potentially eligible for targeted drugs for indication breast 
cancer stratified by early and late phase studies. (C) Summary of the number of patients in the present study that 
were potentially eligible for targeted drugs for any indication, stratified by early and late phase studies as well as 
approved treatments.
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under clinical investigation according to the knowledge base by Dienstmann et al.31. Out of these 162 patients, 
107 (35%) harbored SNV or small indel alterations and 72 (23%) CNV alterations, indicating the relevance of 
profiling both somatic mutations as well as establishing a CNV profile. The most frequent actionable altera-
tion is mutation in PIK3CA, for which three types of therapies are under clinical investigation in “early phase 
studies” (PI3K pathway inhibitors, PI3K alpha inhibitors and AKT inhibitors), and one in a “late phase study” 
(combination of everolimus, trastuzumab, chemotherapy for HER2-positive patients). Further, FGF3 and FGF4 
amplification was detected in 42 patients with a perfect overlap. These genes both reside within 10 000 bases, next 
to each other on chromosome 11, explaining the co-occurrence. These patients could potentially benefit from 
dovitinib37, although current evidence of efficacy is restricted to hormone-receptor positive disease. One “late 
phase” breast cancer study, according to Dienstmann et al., showed an increased pathological complete response 
in the neoadjuvant setting when treating HER2-positive patients also harboring an amplification of TOP2A with 
anthracyclines38. In our ClinSeq study, nine HER2-positive patients harbored amplification in TOP2A. Another 
“late phase” breast cancer study39, showed HER2-positive patients with a hyperactive PI3K pathway, defined by 
somatic mutations in PIK3CA, to benefit from the addition of everolimus to their therapy regimen. In the pres-
ent study, seven HER2-positive patients had somatic mutations in PIK3CA. The great majority of patients with 
actionable mutations in our Clinseq study had alterations in genes matching breast cancer studies in early phase, 
146 (48%), while 16 (5%) were matched with studies in late phase (Fig. 4B). If all cancers in the Dienstmann 
knowledge base were considered, 96 (31%) patients had alterations in genes matching early phase studies, 120 
(39%) late phase studie, and 10 (3%) were approved therapies for other cancers (Fig. 4C, Supplemental Fig. 9). 
DNA sequencing enabled us to detect 162 patients (53%) harboring potentially actionable genetic alterations, 
indicating a broad potential for providing added value through sequencing-based diagnostics in the future.
Discussion
Sequencing-based diagnostics is currently being broadly introduced in the clinical setting as a tool to screen for 
potentially actionable mutations in patients with metastatic disease. It is expected that sequencing-based diag-
nostics also will be implemented in the diagnostic, non-metastatic setting, assuming it performs at least as good 
as current routine diagnostics and provides some added value, while also remaining cost efficient. Provided the 
continuous reduction in sequencing costs over time, sequencing-based diagnostics is expected to be cost efficient 
in the near future, and may even provide a more cost effective alternative than current routine diagnostics even-
tually. The goal with this study was to explore if a DNA- and RNA-based sequencing profile could fulfill these 
criteria, with a focus on ascertaining to what extent sequencing-based diagnostics can be applied as an alternative 
to current routine diagnostics and to what extent added value is generated.
First, we demonstrated that RNAseq-based models could predict ER, PR and HER2 status in high concord-
ance with routine clinical markers, indicating that RNAseq-based molecular characterization of these biomarkers 
has the potential to be translated to the clinic in the future. The great benefit of sequence-based breast cancer 
diagnostics is, however, in providing an improved transcriptomic grade model that stratify patients into two 
distinct groups, and in providing information on additional targetable somatic alterations and information on 
somatic alterations affecting drug metabolism, which may be of importance for dosing the patient correctly or 
avoiding certain compounds. Together these are substantial advantages compared with standard histological 
management. The main benefits and potential of sequencing-based diagnostics are dependent upon implement-
ing and utilizing a wider range of molecular phenotypes (e.g. subtypes, transcriptomic grade, somatic mutations) 
in the clinical setting, while we see little benefit in implementing sequencing-based molecular profiling to merely 
determine the status of current generation routine markers (e.g. ER, PR, HER2), which are currently assayed cost 
effectively using e.g. immunohistochemistry.
The sequencing-based diagnostic approach also provides multiple other advantages in that it is quan-
titative, highly reproducible, objective and amenable to automation. In contrast, routine histopathology is 
semi-quantitative and dependent on subjective human interpretation. Classification of ER, PR and HER2 status 
based on gene expression (qRT-PCR) has previously been assessed with estimated ROC-AUC17 in similar range 
to that observed here, suggesting that irrespective of technology platform (qRT-PCR or RNAseq), classification 
of receptor status from gene expression profiling provides highly concordant results compared with routine 
biomarkers.
Histopathological re-examination of a subset of tumors that were discordant in ER or HER2 status between 
routine biomarkers and sequencing-based diagnostics revealed that a majority (6/10) of discordant ER individ-
uals were reclassified so that ER status became concordant after reclassification. In the case of HER2 discordant 
individuals, two out of six of discordant and re-examined cases were reclassified during reexamination. The CNV 
profile for HER2 discordant individuals revealed that those classified as HER2 negative by RNAseq, while positive 
by IHC/FISH, all had low-grade amplifications of chromosome 17 (Supplemental Figs 3–8), as determined by 
low-pass whole genome DNA sequencing. The efficacy of trastuzumab in breast cancer with low-grade ampli-
fication of ERBB2 is currently being evaluated40. In one of the HER2 discordant individuals, the laterality of the 
profiled tumor could not be uniquely matched with the clinical information, which might explain discordance in 
this patient. Furthermore, the re-examination was not fully blinded and the number of re-examined tumors was 
limited, therefore these results should be interpreted with caution.
Histological grade is routinely used for patient stratification, particularly to inform treatment decisions 
regarding adjuvant chemotherapy. We utilized RNAseq data and multivariate modeling to stratify patients into 
low and high transcriptomic grade, and demonstrated a high concordance for classification of histological grade 
1 and grade 3 individuals. The similarities in subtype and Ki-67 distributions indicate that the TG model stratified 
patients into two groups with highly similar characteristics compared to histological grade 1 and 3. Histological 
grade 2 is considered an intermediary group, which does not provide clinically actionable information41. We 
were able to re-classify histological grade 2 tumors into low and high transcriptomic grade, illustrating how 
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transcriptomic grade can add clinically useful information for the group of patients classified as histological grade 
2. A similar approach has also been proposed previously based on gene-expression data from microarrays28,42.
DNA sequencing was applied to detect somatic mutations and copy number alterations in key genes, including 
ERBB2(HER2) and BRCA1/2, and to assess the proportion of patients in the present study that harbored somatic 
alterations that may be clinically actionable in the future, as defined by ongoing or concluded clinical breast can-
cer trials. DNA sequencing allowed detection of somatic mutations in ERBB2(HER2) that may warrant targeted 
treatment. ERBB2 activating mutations may result in constitutive activation rather than increased expression 
levels. Therefore, the molecular subtype calls may not identify tumors that are driven by ERBB2(HER2) signaling. 
We also investigated BRCA1 and BRCA2 mutation status. Knowledge of BRCA1/2 germline status could impact 
the choice of primary surgery. If a patient is a carrier then more radical surgery, and perhaps preventive surgery 
of the unaffected breast, are potential options. Furthermore, patients with mutations in the BRCA genes are can-
didates to be included in studies evaluating PARP-inhibitors in the adjuvant setting. BRCA-screening provides 
additional benefits in providing opportunity to refer carriers to genetic counseling.
In this study 25 patients (8.1%) were reclassified in respect to ER and HER2 status by RNA-sequencing-based 
diagnostics. These patients might have benefited from an alternative treatment. Lacking a suitable ‘gold standard’ 
reference it is not possible to determine if sequencing-based classification provides more accurate results in this 
case. However, it has previously been reported that gene expression-based diagnostics is more prognostic than 
routine biomarkers17. Sequencing-based molecular profiling also provides a richer source of molecular data, and 
therefore has the potential resolve some ambiguous cases emerging in the current routine pathology setting, for 
example by allowing HER2 status to be determined by both RNA-sequencing and CNV profiling, and by utilizing 
multivariate biomarker panels for determining molecular subtypes (e.g. 50 genes in the PAM50 panel) rather then 
depending single markers (e.g. ER, PR, HER2) as is the case in traditional routine diagnostics. In this study 17 
patients (5.5%) had somatic ERBB2(HER2) activating mutations, BRCA1 or BRCA2 mutations detected by panel 
DNA sequencing, which could impact on treatment. Further 162 patients (53%) had mutations or copy number 
alterations detected by DNA sequencing, which were specified in ongoing or concluded breast cancer clinical 
trials, indicating potential future benefit of sequencing-based diagnostics in a large proportion of patients. In 
addition to actionable somatic alterations, molecular subtyping and improvement in tumor grading systems has 
the potential to provide benefits for even larger groups of patients in the future.
The present study has some limitations; Firstly, the study is based on retrospective biobanked material and 
results have only been replicated in a single external study, consequently the results should be validated in a pro-
spective setting prior to clinical implementation. Secondly, the study is not fully representative for the smallest 
sized tumors, as few small tumors were available for biobanking. However, we do not expect this to impact the 
interpretation of our results since the focus was on assessing concordance between routine diagnostic biomarkers 
and sequencing-based diagnostics. In this study a 10% cutoff for positive ER status was applied, in contrast to the 
1% cutoff recommended in current ASCO-CAP guidelines, as there is currently lack of prospective randomized 
studies demonstrating benefits of a 1% cutoff. However, it has been reported that very few ER positive patients 
have < 10% of cells staining positive2, suggesting that the actual impact of a different cutoff < 10% is expected to 
be minor. Among the main benefits of sequencing-based diagnostics is the ability to detect germline alterations 
affecting drug metabolism, for example in the Dihydropyrimidine Dehydrogenase gene (DPYD)43,44. In future 
clinical implementations it would be highly relevant to ensure inclusion of additional relevant DPYD variants 
as well as other clinically relevant pharmacogenomics loci. The present study was based on fresh frozen (FF) 
tumor tissue, while formalin-fixed paraffin embedded (FFPE) material is standard in the routine clinical setting. 
Although there are quality differences FFPE and FF material, multiple publications demonstrate preserved gene 
expression profiles between FFPE and FF tissues, either by sequencing or other orthogonal technologies45,46. In 
practice, another alternative is to use preservatives, such as RNAlater to enable high quality RNA profiles47.
Our results revealed that breast cancer classification by sequencing-based molecular profiling is highly con-
cordant with current routine diagnostic biomarkers and therefore has the potential to replace current generation 
routine biomarker assays in the clinic in the near future for a majority of patients. Sequencing-based molecular 
characterization also provides additional molecular information with implication on the choice of therapy such 
as molecular subtype and detection of somatic mutations in key genes including BRCA1 and ERBB2 (HER2). 
Furthermore RNA sequencing enabled us to dichotomize patients into high and low tumor grade, which has also 
previously been proposed28,42, but is not yet in clinical routine management. It is our intention to validate the 
results from this study through analysis of further 500 patients in a prospective study.
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